Table 1 Baseline characteristics and overall survival for the overall population, GEP BEP, and mIHC BEP
Characteristic | Overalla (N = 864) | GEP BEP (n = 629) | mIHC BEP (n = 67) |
|---|---|---|---|
Median (range) age, years | 60 (18–82) | 60 (19–81) | 59 (26–78) |
Sex, n (%) | |||
 Male | 537 (62.2) | 396 (63.0) | 45 (67.2) |
 Female | 327 (37.8) | 233 (37.0) | 22 (32.8) |
ECOG performance status, n (%) | Â | Â | Â |
 0 | 302 (35.0) | 228 (36.2) | 20 (29.9) |
 1 | 562 (65.0) | 401 (63.8) | 47 (70.1) |
Cancer type, n (%) | |||
 NSCLC | 105 (12.2) | 57 (9.1) | 25 (37.3) |
 GC | 78 (9.0) | 58 (9.2) | 13 (19.4) |
 EC | 79 (9.1) | 66 (10.5) | 4 (6.0) |
 UC | 152 (17.6) | 127 (20.2) | 25 (37.3) |
 HCC | 68 (7.9) | 50 (7.9) | 0 (0.0) |
 Other | 382 (44.2) | 271 (43.1) | 0 (0.0) |
Patients with any prior anticancer drug therapy, n (%) | Â | Â | Â |
 0–1 | 407 (47.1) | 297 (47.2) | 29 (43.3) |
 2 | 204 (23.6) | 147 (23.4) | 20 (29.9) |
 ≥ 3 | 190 (22.0) | 137 (21.8) | 18 (26.9) |
 Unknown | 63 (7.3) | 48 (7.6) | 0 (0.0) |
Median overall survival, months (95% CI) | 11.1 (9.5–11.7) | 11.1 (9.6–11.9) | 11.2 (6.2–16.1) |